MAPT and Parkinson disease: Using the Parkinson’s Progression Markers Initiative (PPMI), Baek et al. analyzed data from 396 PD patients and 182 HCs and made long-term predictions of concentrations of α-syn, t-Tau, p-Tau, and other biomarkers in CSF, predicated on annual changes when compared to baseline, at which, in agreement with Hall et al., lower levels of t-Tau, p-Tau, and exponentially lower levels of α-syn were observed in the PD group when compared to HCs.